Edition:
United Kingdom

Lonza Group AG (LONN.S)

LONN.S on Virt-X Level 1

312.80CHF
21 Sep 2018
Change (% chg)

CHF-5.90 (-1.85%)
Prev Close
CHF318.70
Open
CHF320.30
Day's High
CHF323.10
Day's Low
CHF312.40
Volume
826,632
Avg. Vol
276,021
52-wk High
CHF328.30
52-wk Low
CHF218.00

Chart for

About

Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life-science industries. The Company divides its activities into four divisions: Life Science Ingredients; Microbial Control; Custom Manufacturing, and Bioscience. The Life Science Ingredients division comprises a... (more)

Overall

Beta: 0.99
Market Cap(Mil.): CHF19,317.19
Shares Outstanding(Mil.): 74.47
Dividend: 2.55
Yield (%): 0.98

Financials

  LONN.S Industry Sector
P/E (TTM): 46.00 85.68 32.76
EPS (TTM): 5.64 -- --
ROI: 5.24 1.79 14.61
ROE: 9.24 3.28 16.33

BRIEF-Lonza Group AG Expands Its Distribution Relationship With Azelis Americas

* SAYS LONZA CONSUMER PRODUCT INGREDIENTS EXPANDS ITS DISTRIBUTION RELATIONSHIP WITH AZELIS AMERICAS

16 Jul 2018

UPDATE 2-European stocks rebound; bank shares lag after poor HSBC, BNP results

* But banks under pressure as HSBC, BNP, SocGen disappoint (Adds detail, updates prices at close)

04 May 2018

Bank shares lag European rebound as poor results hit HSBC, BNP

MILAN, May 4 European shares bounced back on Friday morning as a flurry of company updates rolled in although the heavyweight banking sector was left behind following poor updates from HSBC, BNP Paribas and Societe Generale.

04 May 2018

UPDATE 1-Lonza confirms targets as gets off to good start

ZURICH, May 4 Swiss drug ingredients maker Lonza confirmed its guidance on Friday and said it had got off to a good start this year.

04 May 2018

Lonza confirms targets as Q1 gets off to good start

ZURICH, May 4 Swiss drug ingredients maker Lonza confirmed its guidance on Friday and said it had got off to a good start this year.

04 May 2018

Samsung BioLogics' shares slide again; unit's valuation jump questioned

SEOUL Shares in South Korea's Samsung BioLogics Co Ltd fell 3.5 percent on Thursday, a day after losing almost $6 billion in market value as the contract biotech drugmaker was hit by a regulatory probe into its accounting rules.

03 May 2018

Samsung BioLogics' shares slide again; unit's valuation jump questioned

SEOUL Shares in South Korea's Samsung BioLogics Co Ltd fell 3.5 percent on Thursday, a day after losing almost $6 billion (4.4 billion pounds) in market value as the contract biotech drugmaker was hit by a regulatory probe into its accounting rules.

03 May 2018

Samsung BioLogics' shares slide again; unit's valuation jump questioned

SEOUL, May 3 Shares in South Korea's Samsung BioLogics Co Ltd fell 3.5 percent on Thursday, a day after losing almost $6 billion in market value as the contract biotech drugmaker was hit by a regulatory probe into its accounting rules.

03 May 2018

UPDATE 3-Accounting concerns wipe $6 bln off Samsung BioLogics market value

* Financial watchdog gives preliminary notice to co on measures

02 May 2018

Lonza's virus factory shows gene therapy's Texas-sized promise

ZURICH Swiss drugmaker-for-hire Lonza is betting that trillions of customized viruses made at a giant factory in Texas will be the lucrative raw materials of a medical revolution.

10 Apr 2018

Earnings vs. Estimates